Molecular Pathology, Genomic Sequencing Procedures, and Multianalyte Assays with Algorithmic Analyses: 2019 Update (July 2019)

Why This Topic Matters

It helps readers understand how a rapidly evolving molecular diagnostics area was reflected in CPT for 2019 and where major coding updates occurred across related subsections.

Article Sections

1. July 2019 pages 3-5

   Overview of the 2019 update and the major molecular pathology, genomic sequencing, and multianalyte assay changes covered in the article.

2. Transition of Gene Tests from Tier 2 to Tier 1

   Discusses movement of gene tests between CPT molecular pathology tiers and the overall scope of revisions, additions, and deletions in 2019.

3. EZH2 Gene Analysis

   Covers the addition of CPT reporting options related to EZH2 testing and the general context for those changes.

4. MYD88 Gene Analysis

   Covers the addition of CPT reporting for MYD88 testing and the clinical context described in the update.

5. NUDT15 Gene Analysis

   Covers the addition of CPT reporting for NUDT15 testing and the general purpose of the analysis described.

6. PLCG2 Gene Analysis

   Covers the addition of CPT reporting for PLCG2 testing and the broader disease associations referenced in the update.

7. TERT Gene Analysis

   Covers the addition of CPT reporting for TERT testing and the general oncology context described.

8. TGFBI Gene Analysis

   Covers the addition of CPT reporting for TGFBI testing and the general genetic eye disorder context described.

9. Promoter Methylation Analysis

   Discusses editorial revisions to methylation-related descriptors and the accompanying guideline definitions added to the molecular pathology subsection.

10. Tier 2 Molecular Pathology Procedures

    Summarizes revisions and deletions affecting Tier 2 molecular pathology procedures, including related movements to Tier 1.

11. Genomic Sequencing Procedures and Other Molecular Multianalyte Assays

    Describes the addition of a genomic sequencing procedures panel and the type of content included in that subsection.

12. Multianalyte Assays with Algorithmic Analyses

    Summarizes new Category I and administrative MAAA additions and the general kinds of tests represented.

13. Appendix O

    Covers Appendix O updates, including the relationship between proprietary analyses, administrative codes, and related appendix content.

14. Early Release Dates for Molecular Pathology Tier 2 and Administrative MAAA Codes

    Explains the timing framework for early release of selected CPT molecular pathology and administrative MAAA codes.